Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 13,600 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dermatologic Disorders Clear all
Recruiting Phase 1 Interventional

IKS014 in Advanced Solid Tumors That Express HER2

NCT05872295
View directory record Official record
Conditions
Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
Interventions
IKS014
Drug
Lead sponsor
Iksuda Therapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Newport Beach, California • Boston, Massachusetts • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Not applicable Interventional

Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy Adherence

NCT04054557
View directory record Official record
Conditions
Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage III Breast Cancer AJCC v7
Interventions
Telemedicine, Best Practice, Questionnaire Administration, Quality-of-Life Assessment, Survey Administration, Behavioral Intervention, Educational Intervention
Other · Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
5
States / cities
Washington Township, New Jersey • Philadelphia, Pennsylvania • Torresdale, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 26, 2026, 2:46 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers Results available

Accurate, Rapid and Inexpensive MRI Protocol for Breast Cancer Screening

NCT04877912
View directory record Official record
Conditions
Breast Cancer
Interventions
MRI Abbreviated Scan, Abbreviated MRI Scan
Diagnostic Test
Lead sponsor
University of Chicago
Other
Eligibility
40 Years to 74 Years · Female only
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 26, 2026, 2:46 PM EDT
Active, not recruiting No phase listed Observational

Real-World Effectiveness of Amniotic Membrane Allografts Versus Standard Wound Care in DFU, VLU, and PU

NCT07223281
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU), Venous Leg Ulcers (VLUs), Pressure Ulcers, Bedsores, Decubitus Ulcer
Interventions
Not listed
Lead sponsor
Legacy Medical Consultants
Industry
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
4
States / cities
Colorado Springs, Colorado • Clinton Township, Michigan • Tulsa, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

NCT04091646
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
Roflumilast Foam 0.3%, Vehicle foam
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
22
States / cities
Fremont, California • Santa Monica, California • Coral Gables, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea

NCT04153188
View directory record Official record
Conditions
Erythematotelangiectatic Rosacea
Interventions
The Vbeam® Prima System, Oxymetazoline HCL 1% Cream
Device · Drug
Lead sponsor
Candela Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Charlotte, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Not applicable Interventional

OPTimizing Treatment Focused Genetic Testing IN Cancer

NCT04066361
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer
Interventions
Chatbot, Video Education
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 4 Interventional Results available

Aczone Gel 7.5% in the Treatment of Acne Vulgaris in Patients With Skin of Color

NCT03681470
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Aczone Gel
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 3 Interventional

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis

NCT00814073
View directory record Official record
Conditions
Indolent Systemic Mastocytosis
Interventions
Masitinib, Placebo, Best Supportive Care
Drug · Other
Lead sponsor
AB Science
Industry
Eligibility
18 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Sacramento, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

NCT02858869
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage IV Non-Small Cell Lung Cancer, Stage IV Skin Melanoma, Melanoma of Unknown Primary
Interventions
Pembrolizumab, Stereotactic Radiosurgery
Biological · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 26, 2026, 2:46 PM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab and EDP1503 in Advanced Melanoma

NCT03595683
View directory record Official record
Conditions
Melanoma (Skin), Melanoma
Interventions
Pembrolizumab, EDP1503
Drug · Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 1 Interventional

Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery

NCT02391194
View directory record Official record
Conditions
Breast Cancer
Interventions
AVB-620
Drug
Lead sponsor
Avelas Biosciences, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
La Jolla, California • San Francisco, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 26, 2026, 2:46 PM EDT
Terminated Not applicable Interventional

Effect of a Goal Setting Intervention on Exercise in Women With Metastatic Breast Cancer: An Exploration of The Lipogenic Pathway

NCT01653366
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Physical Activity Goal Setting
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Not applicable Interventional Results available

Health Information Technology (HIT) Enhanced Family History Documentation and Management in Primary Care

NCT01468675
View directory record Official record
Conditions
Colorectal Cancer, Breast Cancer, Coronary Heart Disease, Diabetes
Interventions
Intervention
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
6,075 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 2 Interventional Results available

Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea

NCT00617903
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Azelaic acid, Vehicle foam
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
7
States / cities
Denver, Colorado • Olathe, Kansas • Henderson, Nevada + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 3 Interventional Results available

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

NCT01007942
View directory record Official record
Conditions
HER2/Neu Over-expressing Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions
everolimus, Placebo, vinorelbine, trastuzumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
569 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
43
States / cities
Tucson, Arizona • La Jolla, California • Greenwood Village, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors

NCT01376505
View directory record Official record
Conditions
Malignant Solid Tumour, Breast Cancer, Malignant Tumor of Colon, GIST, Ovarian Cancer
Interventions
HER-2 vaccine, Extension HER-2 vaccine trial at OBD
Biological
Lead sponsor
Robert Wesolowski
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Brain Changes in Psoriasis After Secukinumab Treatment

NCT04717466
View directory record Official record
Conditions
Psoriasis, Healthy
Interventions
Secukinumab
Biological
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Responses to Immunization With Keyhole Limpet Hemocyanin Administered by Scarification and the Intradermal Route

NCT00614731
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
KLH carrier-protein
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 2 Interventional Results available

TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer

NCT03193853
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
Tak-228 & Tak-117, Cisplatin & Nab Paclitaxel
Drug
Lead sponsor
Joyce O'Shaughnessy
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2023 · Synced Oct 26, 2026, 2:46 PM EDT
Terminated No phase listed Observational

Feasibility and Functionality of fPAM Imaging in Melanoma

NCT00776945
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 1Phase 2 Interventional

Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

NCT04902872
View directory record Official record
Conditions
Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer, Colorectal Cancer, Pancreas Cancer, Appendix Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Esophagus Cancer, Urothelial Carcinoma, Sarcoma
Interventions
CBX-12
Drug
Lead sponsor
Cybrexa Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
4
States / cities
New Haven, Connecticut • Austin, Texas • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 26, 2026, 2:46 PM EDT
Recruiting Phase 2 Interventional

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07298395
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
ENV-294, Placebo
Drug
Lead sponsor
Enveda Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
32
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Beverly Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 26, 2026, 2:46 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma

NCT00863395
View directory record Official record
Conditions
Cutaneous T-Cell Lymphoma
Interventions
skin biopsy
Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Oct 26, 2026, 2:46 PM EDT